Watch DocuSign, Broadcom, and Robinhood
DocuSign (DOCU) gave up gains achieved in the last month when shares dropped by 18.97%. DOCU stock dropped when the company cut its full-year guidance.In the first quarter, the software firm earned $0.90 a share. Revenue increased by 8% Y/Y to $763.7 million. In Q2, however, DocuSign is expecting revenue of $777 million to $781 million. The board authorized another $1 billion in share buyback, increasing the total to $1.4 billion.DOCU stock could fall further as investors question the lack of a moat. Customers have plenty of alternative document signing options.Broadcom (AVGO) might break from an uptrend that started in April. Shares traded below $150 back then and above $250 before the earnings report. The company posted revenue of $15 billion. It is guiding $15.8 billion in revenue for Q3. Guidance may potentially rise, once the firm wins business from two or three major customers. Apple (AAPL) is a possible client by the end of this year.Robinhood (HOOD), a trading platform, has a strong customer base. At an investor conference, the company grew equity notional trading volumes by 10% month-over-month. This is an all-time high. Option contract trade volumes increased by 5%. In addition, crypto trading volume grew by 30% from last month.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


